Moyo fetal heart rate effectiveness study

In order to facilitate more prompt identification of a hypoxic fetus, Laerdal Global Health has recently introduced the Moyo FHR monitor. Nevertheless, there exists limited knowledge regarding its efficacy derived from multicenter contextual trials conducted in resource-constrained environments, specifically in Ethiopia. We, therefore aimed to assess the effect of intermittent fetal heart rate monitoring using Moyo Doppler compared to fetoscope in hospitals of Ethiopia, 2023. This randomized -trial [PACTR202305607000259] enrolled 2518 low-risk laboring women in the study during the study period, using a simple randomization technique from September 28, 2022, to February 28, 2023. A total of 1259 and 1259 were followed by Moyo and Pinard fetoscope, respectively. A p < 0.05 was considered significant. The abnormal fetal heart rate was detected among 60 women (5.1%) and 30 women (2.4%) (p = 0.001) in the Moyo and Pinard fetoscope arms, respectively. The Moyo fetal heart rate monitor has demonstrated efficacy in detecting abnormal fetal heart rates when compared to the Pinard fetoscope. Therefore, it is recommended that healthcare systems in low-resource settings consider implementing the Moyo device for fetal heart rate monitoring.